XML 24 R7.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities:      
Net (loss) income $ (7,464) $ 5,140 $ 18,716
Adjustments to reconcile net (loss) income to net cash provided by operating activities:      
Depreciation and amortization 7,056 3,546 2,738
Share based compensation 6,869 6,617 4,549
Deferred income taxes 292 (1,630) (846)
Bad debt expense 324 214 165
(Increase) decrease in operating assets and increase (decrease) in liabilities:      
Accounts receivable (1,742) (41) 509
Inventories (6,417) 13,432 1,965
Prepaid income taxes 675 (182) 278
Prepaid expenses and other current assets (185) 147 (363)
Operating lease right-of-use assets, net 788 0 0
Accounts payable 6,102 (2,292) (12,048)
Sales tax payable (1,101) 1,956 2,928
Accrued expenses and other current liabilities 276 896 (93)
Operating lease liabilities (766) 0 0
Deferred revenue (390) 0 0
Net cash provided by operating activities 4,317 27,803 18,498
Cash flows from investing activities:      
Purchase of minority interest investment in Vetster (300) (5,000) 0
Acquisition of PetCareRx, net of cash acquired (35,859) 0 0
Purchases of property and equipment (4,511) (5,260) (1,752)
Net cash used in investing activities (40,670) (10,260) (1,752)
Cash flows from financing activities:      
Dividends paid (12,437) (24,537) (24,384)
Net cash used in financing activities (12,437) (24,537) (24,384)
Net decrease in cash and cash equivalents (48,790) (6,994) (7,638)
Cash and cash equivalents, at beginning of fiscal year 104,086 111,080 118,718
Cash and cash equivalents, at end of fiscal year 55,296 104,086 111,080
Supplemental disclosure of cash flow information:      
Cash paid for income taxes 130 4,312 6,085
Dividends payable in accrued expenses $ 1,466 $ 1,262 $ 558